fenben lab fenbendazol is the brand name of a broad-spectrum benzimidazole anthelminthic used to treat various parasitic infections in many animal species. Repurposing existing veterinary drugs that show promising results as human cancer therapies can save significant time and cost to develop novel drugs. Besides its antiparasitic action, fenbendazole (methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl) carbamate) is also known to have moderate microtubule depolymerizing activity.
A female dog with metastatic cancer was receiving pembrolizumab monotherapy when she became ill with vomiting and a rash on her face and legs. She reported that her CEA levels had increased so she was referred to our oncology service for further evaluation. Upon interview, she stated that she and her family were taking oral fenbendazole based on information found on social media sites claiming it was effective against cancer.
After the fenbendazole treatment, her clinical and radiographic findings improved markedly and she made a full recovery. We interviewed her family and discovered that they had purchased fenbendazole, which is marketed as an anthelmintic for dogs, from a local pet store based on information found on social media sites that it was effective against cancer.
We determined that fenbendazole, at high concentrations and long incubations, reduces the viability of EMT6 lung cancer cells in vitro by both cytotoxic and cytostatic effects. It also decreases cell migration, proliferation and clonogenicity. Furthermore, fenbendazole significantly enhances the radiation-sensitivity of EMT6 cells in both aerobic and hypoxic conditions in comparison to control cells. fenben lab fenbendazol